Boston, MA 02/27/2014 (wallstreetpr) – La Jolla Pharmaceutical Company (NASDAQ:LJPC) which is a $35.15 million market capped biopharma company recently announced allowed patent notice. It is now emerging that the allowed patent covers the company’s leading product candidate.
The company is concerned with the treatments aimed at inhibiting the activity of galectins so as to achieve treatment of cancer and chronic organ failures in humans. The patent in question therefore covers the treatment methods for chronic inflammation with the aim of modified pectin.The U.S. Patent and Trademark Office issued patent application number 13/888,158 for LIPC’s latest chronic treatment technology.
Patent coverage
La Jolla Pharmaceutical Company (NASDAQ:LJPC) announced that the patent covers GCS-100, which is its lead product candidate. The product is currently under Phase 2 clinical study in a randomized fashion in patients with CDK. The results from this study pointing out on its endpoint efficacy are expected for release next month.
The patent that La Jolla Pharmaceutical Company (NASDAQ:LJPC) has just got allowed notice for expires in 2025, that is without considering the extension term for the patent. The patent offers protection for chronic inflammation treatment through the administering of modified pectin.
It is understood that chronic inflammation as direct link to the cause of fibrosis. Thus, the newly allowed patent provides the proprietary strength for the use of modified pectin in the treatment of organ diseases in the heart, liver, kidney and lungs, among other organs that come as a result of chronic inflammation.
Intellectual portfolio
La Jolla Pharmaceutical Company (NASDAQ:LJPC) has a portfolio of intellectual property that covers among other things, modified pectin composition. The company is also having pending applications for patents that seek additional modified pectin composition.
The solutions that are being sought by La Jolla Pharmaceutical Company (NASDAQ:LJPC) have the potential of being a relief to patients of kidney and liver conditions as well as other organ diseases.
The candidate drug GCS-100 that is being developed by La Jolla Pharmaceutical Company (NASDAQ:LJPC) is promising to prevent and even reverse the chronic liver conditions by mitigating fibrosis. Thus, the drug bears extensive clinical benefit to patients and even healthcare professionals.
